Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 5.65 billion in funding
October 23, 2016
Share
Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) announced a private placement of 27th unregistered coupon unguaranteed private placement convertible bonds for gross proceeds of KRW 5,650,000,000 on October 24, 2016. The transaction included participation from 10 individual investors, including Taeho Kim for KRW 3,300,000,000, Wonseok Jung for KRW 500,000,000, and Hobum Song for KRW 500,000,000. The bonds are issued at par and will mature on October 24, 2019. The bonds carry yield to maturity of 4% and no annual coupon. The bonds can be fully converted into common shares of the company at a fixed conversion price of KRW 4,893 per share from October 24, 2017 to September 24, 2019. The transaction has been approved by the board of directors of the company.
SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.